Advertisement

Immune Dysregulation in Alagille Syndrome: A Feature of the Evolving Phenotype

  • Alastair BakerEmail author
Chapter

Abstract

The diagnosis and condition including those involving understanding of Alagille syndrome have evolved over more than 40 years giving important insights into other conditions including liver, cardiac, vascular, renal, eye and growth. Recently a new mechanism involving Jagged1, Notch1, and CD46 has been described linking the complement system to T cell progression through normal inflammation to resolution. A proportion of Alagille patients have been described as exhibiting excessive infections or inflammation including a small number with rare chronic inflammatory conditions. Four patients with ALGS having had recurrent infections have been described with an immune profile compatible with a persistent pro-inflammatory immune state related to failure of the Jagged1-Notch-CD46 system. Studies to elucidate the prevalence, cohort clinical significance, and optimal management have still to be undertaken.

Keywords

Immune regulation Complement CD46 IL10 Th1 vs Th2 lymphocytes 

References

  1. 1.
    Alagille D, Estrada A, Hadchouel M, Gautier M, Odièvre M, Dommergues JP. Syndromic paucity of interlobular bile ducts (Alagille syndrome or arteriohepatic dysplasia): review of 80 cases. J Pediatr. 1987;110(2):195–200.Google Scholar
  2. 2.
    Watson GH, Miller V. Arteriohepatic dysplasia: familial pulmonary arterial stenosis with neonatal liver disease. Arch Dis Child. 1973;48(6):459–66.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Alagille D, Odièvre M, Gautier M, Dommergues JP. Hepatic ductular hypoplasia associated with characteristic facies, vertebral malformations, retarded physical, mental, and sexual development, and cardiac murmur. J Pediatr. 1975;86(1):63–71.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Martin SR, Garel L, Alvarez F. Alagille's syndrome associated with cystic renal disease. Arch Dis Child. 1996;74(3):232–5.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Bérard E, Sarles J, Triolo V, Gagnadoux MF, Wernert F, Hadchouel M, Niaudet P. Renovascular hypertension and vascular anomalies in Alagille syndrome. Pediatr Nephrol. 1998;12(2):121–4.PubMedCrossRefGoogle Scholar
  6. 6.
    Nischal KK, Hingorani M, Bentley CR, Vivian AJ, Bird AC, Baker AJ, Mowat AP, Mieli-Vergani G, Aclimandos WA. Ocular ultrasound in Alagille syndrome: a new sign. Ophthalmology. 1997;104(1):79–85.PubMedCrossRefGoogle Scholar
  7. 7.
    Hingorani M, Nischal KK, Davies A, Bentley C, Vivian A, Baker AJ, Mieli-Vergani G, Bird AC, Aclimandos WA. Ocular abnormalities in Alagille syndrome. Ophthalmology. 1999;106(2):330–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Lykavieris P, Crosnier C, Trichet C, Meunier-Rotival M, Hadchouel M. Bleeding tendency in children with Alagille syndrome. Pediatrics. 2003;111(1):167–70.PubMedCrossRefGoogle Scholar
  9. 9.
    Kamath BM, Spinner NB, Emerick KM, Chudley AE, Booth C, Piccoli DA, Krantz ID. Vascular anomalies in Alagille syndrome: a significant cause of morbidity and mortality. Circulation. 2004;109(11):1354–8.CrossRefGoogle Scholar
  10. 10.
    Sondheimer JM. Bleeding is a risk in Alagille syndrome. J Pediatr Gastroenterol Nutr. 2003;36(4):509.PubMedCrossRefGoogle Scholar
  11. 11.
    Kamath BM, Spinner NB, Emerick KM, Chudley AE, Booth C, Piccoli DA, Krantz ID. Vascular anomalies in Alagille syndrome: a significant cause of morbidity and mortality. Circulation. 2004;109(11):1354–8.CrossRefGoogle Scholar
  12. 12.
    Woolfenden AR, Albers GW, Steinberg GK, Hahn JS, Johnston DC, Farrell K. Moyamoya syndrome in children with Alagille syndrome: additional evidence of a vasculopathy. Pediatrics. 1999;103(2):505–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Narula P, Gifford J, Steggall MA, Lloyd C, Van Mourik ID, Mckiernan PJ, Willshaw HE, Kelly D. Visual loss and idiopathic intracranial hypertension in children with Alagille syndrome. J Pediatr Gastroenterol Nutr. 2006;43(3):348–52.PubMedCrossRefGoogle Scholar
  14. 14.
    Quiros-Tejeira RE, Ament ME, Heyman MB, Martin MG, Rosenthal P, Hall TR, McDiarmid SV, Vargas JH. Variable morbidity in Alagille syndrome: a review of 43 cases. J Pediatr Gastroenterol Nutr. 1999;29(4):431–7.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Tilib Shamoun S, Le Friec G, Spinner N, Kemper C, Baker AJ. Immune dysregulation in Alagille syndrome: a new feature of the evolving phenotype. Clin Res Hepatol Gastroenterol. 2015;39(5):566–9.PubMedCrossRefGoogle Scholar
  16. 16.
    McCright B, Lozier J, Gridley T. A mouse model of Alagille syndrome: Notch2 as a genetic modifier of Jag1 haploinsufficiency. Development. 2002;129(4):1075–82.Google Scholar
  17. 17.
    Kopan R, Ilagan MX. Notch signaling pathway: unfolding the activation mechanism. Cell. 2009;137(2):216–33.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Barrantes IB, Elia AJ, Wünsch K, Hrabe de Angelis MH, Mak TW, Rossant J, Conlon RA, Gossler A, de la Pompa JL. Interaction between Notch signalling and Lunatic fringe during somite boundary formation in the mouse. Curr Biol. 1999;9(9):470–80.PubMedCrossRefGoogle Scholar
  19. 19.
    High FA, Jain R, Stoller JZ, Antonucci NB, Lu MM, Loomes KM, Kaestner KH, Pear WS, Epstein JA. Murine Jagged1/Notch signaling in the second heart field orchestrates Fgf8 expression and tissue-tissue interactions during outflow tract development. J Clin Invest. 2009;119(7):1986–96.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Roca C, Adams RH. Regulation of vascular morphogenesis by Notch signaling. Genes Dev. 2007;21(20):2511–24.PubMedCrossRefGoogle Scholar
  21. 21.
    Yamamoto M, Morita R, Mizoguchi T, Matsuo H, Isoda M, Ishitani T, Chitnis AB, Matsumoto K, Crump JG, Hozumi K, Yonemura S, Kawakami K, Itoh M. Mib-Jag1-Notch signalling regulates patterning and structural roles of the notochord by controlling cell-fate decisions. Development. 2010;137(15):2527–37.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Hofmann JJ, Zovein AC, Koh H, Radtke F, Weinmaster G, Iruela-Arispe ML. Jagged1 in the portal vein mesenchyme regulates intrahepatic bile duct development: insights into Alagille syndrome. Development. 2010;137(23):4061–72.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Tanimizu N, Miyajima AJ. Notch signaling controls hepatoblast differentiation by altering the expression of liver-enriched transcription factors. Cell Sci. 2004;117(Pt 15):3165–74.CrossRefGoogle Scholar
  24. 24.
    Hao J, Koesters R, Bouchard M, Gridley T, Pfannenstiel S, Plinkert PK, Zhang L, Praetorius M. Jagged1-mediated Notch signaling regulates mammalian inner ear development independent of lateral inhibition. Acta Otolaryngol. 2012;132(10):1028–35.PubMedCrossRefGoogle Scholar
  25. 25.
    Janasek D, Spohn U, Beckmann D, Powell BC, Passmore EA, Nesci A, Dunn SM. The Notch signalling pathway in hair growth. Mech Dev. 1998;78(1):189–192(4).Google Scholar
  26. 26.
    Irvin DK, Nakano I, Paucar A, Kornblum HI. Patterns of Jagged1, Jagged2, Delta-like 1 and Delta-like 3 expression during late embryonic and postnatal brain development suggest multiple functional roles in progenitors and differentiated cells. J Neurosci Res. 2004;75(3):330–43.PubMedCrossRefGoogle Scholar
  27. 27.
    Gentle ME, Rose A, Bugeon L, Dallman MJ. Noncanonical Notch signaling modulates cytokine responses of dendritic cells to inflammatory stimuli. J Immunol. 2012;189(3):1274–84.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Yoon KJ, Lee HR, Jo YS, An K, Jung SY, Jeong MW, Kwon SK, Kim NS, Jeong HW, Ahn SH, Kim KT, Lee K, Kim E, Kim JH, Choi JS, Kaang BK, Kong YY. Mind bomb-1 is an essential modulator of long-term memory and synaptic plasticity via the Notch signaling pathway. Mol Brain. 2012;5(1):40.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Nijjar SS, Wallace L, Crosby HA, Hubscher SG, Strain AJ. Altered Notch ligand expression in human liver disease: further evidence for a role of the Notch signaling pathway in hepatic neovascularization and biliary ductular defects. Am J Pathol. 2002;160(5):1695–703.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Boulter L, Govaere O, Bird TG, Radulescu S, Ramachandran P, Pellicoro A, Ridgway RA, Seo SS, Spee B, Van Rooijen N, Sansom OJ, Iredale JP, Lowell S, Roskams T, Forbes SJ. Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease. Nat Med. 2012;18(4):572–9.  https://doi.org/10.1038/nm.2667.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Chigurupati S, Arumugam TV, Son TG, Lathia JD, Jameel S, Mughal MR, Tang SC, Jo DG, Camandola S, Giunta M, Rakova I, McDonnell N, Miele L, Mattson MP, Poosala S. Involvement of Notch signaling in wound healing. PLoS One. 2007;2(11):e1167.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Janasek D, Spohn U, Beckmann D, Powell BC, Passmore EA, Nesci A, Dunn SM. The Notch signalling pathway in hair growth. Mech Dev. 1998;78(1):189–192(4).Google Scholar
  33. 33.
    Koyanagi A, Sekine C, Yagita H. Expression of Notch receptors and ligands on immature and mature T cells. Biochem Biophys Res Commun. 2012;418:799–805.PubMedCrossRefGoogle Scholar
  34. 34.
    Helbig C, Gentek R, Backer RA, de Souza Y, Derks IA, Eldering E, Wagner K, Jankovic D, Gridley T, Moerland PD, Flavell RA, Amsen D. Notch controls the magnitude of T helper cell responses by promoting cellular longevity. Proc Natl Acad Sci U S A. 2012;109(23):9041–6.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Liszewski K, Atkinson JP. Complement regulator CD46: genetic variants and disease associations. Hum Genomics. 2015;9(1):7.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Cattaneo R. Four viruses, two bacteria, and one receptor: membrane cofactor protein (CD46) as pathogens' magnet. J Virol. 2004;78(9):4385–8.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Ni Choileain S, Weyand NJ, Neumann C, Thomas J, So M, Astier AL. The dynamic processing of CD46 intracellular domains provides a molecular rheostat for T cell activation. PLoS One. 2011;6(1):e16287.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Astier AL, Meiffren G, Freeman S, Hafler DA. Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J Clin Invest. 2006;116(12):3252–7.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Bordon Y. T cell responses: Jagged gives an edge to TH1 cells. Nat Rev Immunol. 2012;12:806–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Kemper C, Atkinson JP. T-cell regulation: with complements from innate immunity. Nat Rev Immunol. 2007;7(1):9–18.PubMedCrossRefGoogle Scholar
  41. 41.
    Astier AL. CD46 processing: a means of expression. Immunobiology. 2012;217(2):169–75.PubMedCrossRefGoogle Scholar
  42. 42.
    Le Friec G, Vantourout P, Roberts A, Fuchs A, Jackson I, Suddason T, Lord G, Atkinson JP, Cope A, Hayday A, Kemper C. Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells. Nat Immunol. 2010;11(9):862–71.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Astier AL, Meiffren G, Freeman S, Hafler DA. Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J Clin Invest. 2006;116(12):3252–7.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Couzi L, Contin-Bordes C, Marliot F, Sarrat A, Grimal P, Moreau JF, Merville P, Fremeaux-Bacchi V. Inherited deficiency of membrane cofactor protein expression and varying manifestations of recurrent atypical hemolytic uremic syndrome in a sibling pair. Am J Kidney Dis. 2008;52(2):e5–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Mohlin FC, Mercier E, Fremeaux-Bacchi V, Liszewski MK, Atkinson JP, Gris JC, et al. Analysis of genes coding for CD46, CD55, and C4b-binding protein in patients with idiopathic, recurrent, spontaneous pregnancy loss. Eur J Immunol. 2013;43(6):1617–29.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Bora NS, Matta B, Lyzogubov VV, Bora PS. Relationship between the complement system, risk factors and prediction models in age-related macular degeneration. Mol Immunol. 2015;63(2):176–83.PubMedCrossRefGoogle Scholar
  47. 47.
    Kellermayer R. Epigenetics and the developmental origins of inflammatory bowel diseases. Can J Gastroenterol. 2012;26(12):909–15.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Mannion M, Zolak MK, Beukelman DR, T. and Cron RQ. Sarcoidosis in a young child with Alagille syndrome: a case report. Pediatr Rheumatol. 2012;10:32.CrossRefGoogle Scholar
  49. 49.
    Kavukçu S, Demir K, Soylu A, Anal O, Saatçi O, Göktay Y. A case of Takayasu disease with findings of incomplete Alagille syndrome. Rheumatol Int. 2005;25:555–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Emerick KM, Rand EB, Goldmuntz E, Krantz ID, Spinner NB, Piccoli DA. Features of Alagille syndrome in 92 patients: frequency and relation to prognosis. Hepatology. 1999;29:822–9.CrossRefGoogle Scholar
  51. 51.
    Oude Elferink RP, Kremer AE, Martens JJ, Beuers UH. The molecular mechanism of cholestatic pruritus. Dig Dis. 2011;29(1):66–71.PubMedCrossRefGoogle Scholar
  52. 52.
    Rishe E, Azarm A, Bergasa NV. Itch in primary biliary cirrhosis: a patients’ perspective. Acta Derm Venereol. 2008;88(1):34–7.PubMedCrossRefGoogle Scholar
  53. 53.
    Le Friec G, Sheppard D, Whiteman P, Karsten CM, Shamoun SA, Laing A, Bugeon L, Dallman MJ, Melchionna T, Chillakuri C, Smith RA, Drouet C, Couzi L, Fremeaux-Bacchi V, Köhl J, Waddington SN, McDonnell JM, Baker AJ, Handford PA, Lea SM, Kemper C. The CD46-Jagged1 interaction is critical for human T(H)1 immunity. Nat Immunol. 2012;13(12):1213–21.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Kacser H, Burns JA. The molecular basis of dominance. Genetics. 1981;97:639–66.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Seidman JG, Seidman C. Transcription factor haploinsufficiency: when half a loaf is not enough. J Clin Invest. 2002;109:451–5.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Jaramillo DF, Proctor M, Kumm J, Hillenmeyer ME, Davis RW, Nislow C, Giaever G. Mechanisms of Haploinsufficiency Revealed by Genome-Wide Profiling in Yeast. Genetics. 2005;169(4):1915–25.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Papp B, Pal C, Hurst LD. Dosage sensitivity and the evolution of gene families in yeast. Nature. 2003;424:194–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Robinson DS. The role of the T cell in asthma. J Allergy Clin Immunol. 2010;126(6):1081–91.PubMedCrossRefGoogle Scholar
  59. 59.
    Kim JS, Sampson HA. Food allergy: a glimpse into the inner workings of gut immunology. Curr Opin Gastroenterol. 2012;28(2):99–103.PubMedCrossRefGoogle Scholar
  60. 60.
    Kamath BM, Yin W, Miller H, Anand R, Rand EB, Alonso E, Bucuvalas J, Studies of Pediatric Liver Transplantation. Outcomes of liver transplantation for patients with Alagille syndrome: the studies of pediatric liver transplantation experience. Liver Transpl. 2012;18(8):940–8.  https://doi.org/10.1002/lt.23437.CrossRefGoogle Scholar
  61. 61.
    Meiler F, Zumkehr J, Klunker S, Ruckert B, Akdis CA, Akdis M. In vivo switch to IL-10 secreting T regulatory cells in high dose allergen exposure. J Exp Med. 2008;205(12):2887–98.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Kronsten V, Fitzpatrick E, Baker A. Management of cholestatic pruritus in paediatric patients with Alagille syndrome: the King’s College Hospital experience. J Pediatr Gastroenterol Nutr. 2013;57(2):149–54.PubMedCrossRefGoogle Scholar
  63. 63.
    Schaefer B, Schaefer F, Wittmer D, Engelmann G, Wenning D, Schmitt CP. Molecular Adsorbent Recirculating System dialysis in children with cholestatic pruritus. Pediatr Nephrol. 2012;27(5):829–34.PubMedCrossRefGoogle Scholar
  64. 64.
    Kamath BM, Podkameni G, Hutchinson AL, Leonard LD, Gerfen J, Krantz ID, Piccoli DA, Spinner NB, Loomes KM, Meyers K. Renal anomalies in Alagille syndrome: a disease-defining feature. Am J Med Genet A. 2012;0(1):85–9.CrossRefGoogle Scholar
  65. 65.
    Kamath BM, Spinner NB, Rosenblum ND. Renal involvement and the role of Notch signalling in Alagille syndrome. Nat Rev Nephrol. 2013;9(7):409–18.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Russo PA, Ellis D, Hashida Y. Renal histopathology in Alagille's syndrome. Pediatr Pathol. 1987;7(5–6):557–68.PubMedCrossRefGoogle Scholar
  67. 67.
    Lilian M, Palma P, Langman CB. Critical appraisal of eculizumab for atypical hemolytic uremic syndrome. J Blood Med. 2016;7:39–72.Google Scholar
  68. 68.
    Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol. 2013;190(8):3839–47.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Kamath BM, Schwarz KB, Hadzić N. Alagille syndrome and liver transplantation. J Pediatr Gastroenterol Nutr. 2010;50(1):11–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.King’s College HospitalLondonUK

Personalised recommendations